In Vivo T Cell-Targeting Nanoparticle Drug Delivery Systems: Considerations for Rational Design.
Paula M Cevaal, Abdalla Ali, Ewa Czuba-Wojnilowicz1
1ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and the Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria 3010, Australia.
ACS Nano
|February 18, 2021
Summary
Nanoparticles offer promising therapeutic delivery to T cells, crucial for immunity and disease treatment. Engineering strategies are key to overcoming challenges in targeting these nonphagocytic cells for improved treatments.
Area of Science:
- Nanomedicine
- Immunology
- Cellular Biology
Background:
- T cells are vital for immune responses and tissue repair.
- T cells are implicated in various diseases, including cancers, viral infections, and inflammatory conditions.
- Nanoparticles are increasingly utilized as carriers for therapeutic delivery to T cells.
Purpose of the Study:
- To review the challenges and strategies for delivering nanoparticles to T cells.
- To highlight engineering approaches for enhancing nanoparticle internalization by T cells.
- To discuss applications in treating T cell-related diseases like lymphoma and HIV.
Main Methods:
- Review of current literature on nanoparticle-T cell interactions.
- Discussion of physiological barriers to T cell targeting.
- Analysis of engineering strategies for nanoparticle delivery.
Main Results:
- Nanoparticle delivery to T cells faces challenges due to their nonphagocytic nature.
- Various approaches exist to improve nanoparticle delivery and T cell targeting.
- Ligand-based targeting is a key strategy for enhancing nanoparticle internalization.
Conclusions:
- Effective nanoparticle delivery to T cells is crucial for developing novel therapies.
- Engineering nanomaterials to target or modulate T cell function holds significant therapeutic potential.
- Overcoming delivery barriers will advance treatments for T cell-mediated diseases.
